Drug development and nda
enantiomer
Peclinical development2003
2010-03-26 CNS Acting Drugs
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May2011
new biological targets by prathyusha .m
Harish
Pharmaceutical Marketing - State of the Industry in 2011
Mary Ellen Turner MD, MPH Vice-President Global Safety Surveillance & Epidemiology Risk Management: Practical Implications for Pharmaceutical Manufacturers.
Antibiotic Incentives For Global Health WHO CEWG 2011 Kevin Outterson Boston University Schools of Law & Public Health Harvard Center for Communicable.
Dr. Vajira H. W. Dissanayake MBBS (Colombo), PhD (Nottingham) Senior Lecturer, Human Genetics Unit & Joint-secretary, Ethics review committee Faculty of.
NLM for Health Sciences Student Session 4 – More from the NLM
